← All trials
NCT01709760
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2012
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 91
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- TSH Biopharm Corporation LimitedLead sponsor
- Taichung Veterans General HospitalOverall official - principal investigator
- Chang Gung UniversityOverall official - principal investigator
- Chung Shan Medical UniversityOverall official - principal investigator
- Changhua Christian HospitalOverall official - principal investigator
- Tzu Chi UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.